Banca de DEFESA: ÍZOLA MORAIS DE MEDEIROS RAMALHO

Uma banca de DEFESA de DOUTORADO foi cadastrada pelo programa.
STUDENT : ÍZOLA MORAIS DE MEDEIROS RAMALHO
DATE: 19/12/2022
TIME: 14:00
LOCAL: REMOTA - https://meet.google.com/szr-ttzn-jeo
TITLE:

CURRENT TRENDS ON CANNABIDIOL DELIVERY SYSTEMS: WHERE ARE WE AND WHERE ARE WE GOING?

KEY WORDS:

Nanolipospheres; ethosomes; microparticles; inclusion complex; conjugates; nanoparticles; nanocrystals

PAGES: 50
BIG AREA: Ciências da Saúde
AREA: Farmácia
SUMMARY:

Introduction: Cannabidiol (CBD), a phytocannabinoid from Cannabis sativa, has several therapeutic properties. However, its high lipophilicity, metabolization, and instability impair its bioavailability and translational use in clinical settings. Several advanced drug delivery systems (ADDSs) have been evaluated as CBD carriers to overcome these drawbacks. These systems can improve the CBD dissolution profile, protect it against metabolization, and produce a site-specific release, increasing its bioavailability and making CBD administration clinically effective. Areas covered: This review summarizes scientific reports on cannabidiol advanced delivery systems (CBDADSs) that have been (i) developed, and (ii) applied therapeutically; reports published in the main scientific databases until January 2020 were included. Studies without experimental data and/or published in languages other than English were excluded. Moreover, pharmaceutical technology tools in CBD therapeutic use have been discussed, emphasizing the clinical translation of CBD carrier use. Expert opinion: Studies reporting CBD-ADS use for medicinal applications were reviewed and revealed multifaceted systems that can overcome the physicochemical drawbacks of CBD and improve its biological activities. Therefore, researchers concluded that the developed CBD-ADS can be used as an alternative to traditional formulations because they show comparable or superior effectiveness in treatment protocols. Although several criteria remain to be met, our findings emphasize the potential of CBD-ADSs for translational therapeutics, particularly for neurological disorders.

COMMITTEE MEMBERS:
Interno - 346138 - ALDO DA CUNHA MEDEIROS
Interna - 1199080 - ANA KATHERINE DA SILVEIRA GONCALVES DE OLIVEIRA
Presidente - 1178187 - ERYVALDO SOCRATES TABOSA DO EGITO
Externo à Instituição - GUILHERME MARTINS GELFUSO - UnB
Externo à Instituição - HENRIQUE RODRIGUES MARCELINO - UFBA
Externo à Instituição - ÉVERTON DO NASCIMENTO ALENCAR - UFG